The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1181
April 26, 2004
View Complete Issue         Table of Contents 2019 
Epinastine Ophthalmic Solution (Elestat)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Epinastine Ophthalmic Solution (Elestat)
April 26, 2004 (Issue: 1181)
Epinastine HCl, an H1-receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution (Elestat - Allergan/Inspire) for prevention of itching associated with allergic conjunctivitis. The drug is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Epinastine Ophthalmic Solution (Elestat)
Article code: 1181c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.